Difference between revisions of "Non-small cell lung cancer, RET-positive"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 50%; text-align:center;"" to "{| class="wikitable" style="width: 40%; text-align:center;"") |
Warner-admin (talk | contribs) m |
||
Line 1: | Line 1: | ||
− | { | + | {{#lst:Section editor transclusions|thoracic}} |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |} | ||
Note: these are regimens tested in biomarker-specific populations, please see the '''[[Non-small cell lung cancer|main NSCLC page]]''' for other regimens. | Note: these are regimens tested in biomarker-specific populations, please see the '''[[Non-small cell lung cancer|main NSCLC page]]''' for other regimens. | ||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" |
Revision as of 15:30, 11 October 2021
Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
7 regimens on this page
7 variants on this page
|
Advanced or metastatic disease
Pralsetinib monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Unpublished (ARROWRET) | Phase I/II (RT) |
Note: this trial is denoted as ARROWRET to distinguish from other trials of the same name. There are no publications yet, to our knowledge.
Biomarker eligibility criteria
- RET fusion positive
Targeted therapy
References
- ARROW: NCT03037385
Selpercatinib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Evidence |
---|---|
Drilon et al. 2020 (LIBRETTO-001) | Phase I/II (RT) |
Biomarker eligibility criteria
- RET fusion positive
Targeted therapy
- Selpercatinib (Retevmo) with or without food, as follows:
- Less than 50 kg: 120 mg PO twice per day
- 50 kg or more: 160 mg PO twice per day
Continued indefinitely
References
- LIBRETTO-001: Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Aug 27;383(9):813-824. link to original article PubMed NCT03157128